More information: Abstract LBA 02: Concurrent chemoradiation +/- atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005 ...

Genentech's atezolizumab has been granted a fast review in the US for some cases of advanced non-small cell lung cancer. The US Food and Drug Administration has granted a Priority Review for the ...

Atezolizumab is a monoclonal antibody that works to hinder interactions between programmed death ligand-1 (PD-L1) and programmed cell death-1 (PD-1) receptors, which are overexpressed in a variety ...

Lung cancer is the third leading cause of cancer ... Immunotherapy drugs used for extensive-stage SCLC include: Tecentriq (atezolizumab) Imfinzi (durvalumab) Imdelltra (tarlatamab) If cancer ...

The first patient with small cell lung cancer has been dosed in a trial of peluntamig ... to evaluate peluntamig in combination with the anti-PD-L1 therapy Tecentriq (atezolizumab). Dose-limiting ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is ...

Thymic carcinoma, a rare cancer, is often associated with poor prognosis in advanced or recurrent stages. However, its rarity ...

Read more about A trial of MK-7684A and chemotherapy for small cell lung cancer (KeyVibe-008) A trial of lurbinectedin and atezolizumab to improve treatment for small cell lung cancer (IMforte) This ...